MedTrace Logo

The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

NCT02796183 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-06-10

No results posted yet for this study

Summary

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

Conditions

Interventions

DRUG

Subconjunctival bevacizumab (Altuzan)

Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.

Sponsors & Collaborators

  • Ondokuz Mayıs University

    collaborator OTHER

  • Neon Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-04-30
Completion
2016-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02796183 on ClinicalTrials.gov